A multi-billion AUM firm based in the USA is known for investing in technologies that change paradigms. The firm is currently investing out of a $1 billion venture fund for later stage investments and a $400 million for seed-stage investments. The firm has invested across a multitude of industries, including healthcare. Within healthcare, the firm is agnostic, choosing to select companies based on their potential impact. The firm will invest globally and generally prefer Seed and Series A opportunities for new investments.
While the firm is agnostic to sector and indication, the firm does have several areas of particularly high interest. Currently, the firm is interested in nucleic acid-based technologies and therapeutics, manufacturing and automation tools, and discovery tools. While the firm is open to any indication, the firm does prefer to invest in less crowded disease areas.
The firm places a strong emphasis on the team when investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply